The largest single-center experience with the leading LVAD in China shows high survival with low complication rates, demonstrating that CH-VAD is safe and efficient in providing long-term support for patients with end-stage heart failure.

2024年11月1日 · Left ventricular assist devices (LVADs) are well-established for treating end-stage heart failure, but this therapy is only available to Chinese patients in recent years. The CH-VAD is the first used fully magnetically levitated pump in China. This study reports the long-term outcomes of a cohort supported by the CH-VAD for the first time.

2023年4月17日 · 国内LVAD产业尚处于起步阶段，从2017年开始，我国已有多款国产LVAD设备，其中3款已经获批上市，分别为重庆永仁心（EVAHEART）、苏州同心（CH-VAD）和航天泰心（Heartcon），另有深圳核心医疗人工心脏产品Corheart 6有望于今年获批上市。

2024年3月23日 · The CH-VAD left ventricular assist system (CH Biomedical, Su Zhou, China) is the latest generation of fully magnetically levitated centrifugal-flow LVAD in China (Figure 4C). In this critically ill case, the CH-VAD pump provided excellent circulatory support without hemocompatibility-related adverse events.

The CH-VAD (CH Biomedical Inc, Suzhou, China), a fully magnetically suspended LVAD system, has been introduced with an in vitro study that shows shear-induced hemolysis and platelet activation acceptable relative to 2 other LVADs that are not fully magnetically levitated. 8 The first implantation of CH-VAD in a man was performed on June 26 ...

This milestone begins commercialization of the new generation LVAD with advanced full magnetic levitation technology in China, opening a new era in heart failure treatment. Dr. Chen Chen, founder and CEO of the company, said: "Today's ventricular assist devices are not only to save lives, but also to make patients return to their normal and ...

2024年11月21日 · 本次大会上，多位中国专家分享了LVAD临床应用经验以及研究数据，向亚洲与世界展示机械循环辅助领域的中国成果。 研究显示，部分心衰患者植入LVAD后心功能可逐渐恢复至正常水平。 对这部分患者而言，按照设计的方案撤除LVAD可以保证安全有效。 在11月14日上午的日程中， 中国医学科学院阜外医院卿平教授 汇报了一项单中心、回顾性、观察性研究结果。 研究纳入了共147名植入LVAD的患者，遵照阜外医院 “患者评估-逐渐降低转速-外科手术撤泵” 的 …

BACKGROUND: Left ventricular assist devices (LVADs) are well-established for treating end-stage heart failure, but this therapy is only available to Chinese patients in recent years. The CH-VAD is the first used fully magnetically levitated pump in China.

2025年1月7日 · The CH-VAD is a fully magnetically levitated left ventricular assist device (LVAD) designed for optimized hemocompatibility. This study evaluates the clinical outcomes of 77 patients implanted with the CH-VAD across seven centers in China from June 2022 to June 2024.

2023年8月26日 · 近日，中国心室辅助装置专家共识委员会组织专家，总结了 lvad的适应证与禁忌证、手术时机的选择、术前评估、术前状态优化等最新认识及规范，以期指导临床对此新疗法的规范化应用。 01、lvad 植入术的适应证与禁忌证及各种应用场景